🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ILMN ILMN

Company Profile ↓
$199.87
+103.04% 1Y
P/E36.67
52W High$205.10
52W Low$91.00
EPS (TTM)$5.45

Company Overview

ILMN (ILMN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 31.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 16.0%.

Consistent Profit Growth

Net profit has compounded at 19.8% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 12.7% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 19.6%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $4.34B (-0.7% YoY); net profit $850.00M.
  • Trailing 12 Months Year-on-year growth — revenue -0.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.7%, profit CAGR 19.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:12.65%
1 Year:-0.66%

Compounded Profit Growth

5 Years:19.80%
1 Year:-

Stock Price Performance

1 Year:+103.04%
6 Months:+47.58%
3 Months:+43.72%
1 Month:+4.23%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 95% of range
$91.00 $205.10
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)59.22 · Neutral
Price Performance
1M+4.23%
3M+43.72%
6M+47.58%
1Y+103.04%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 31.2%.
  • Compounding revenue at 12.7% over 5 years.
  • Profit CAGR of 19.8% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
36.67
Industry PE
-
Forward P/E est.
30.61
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
12.65%
Profit 5Y
19.80%
Revenue (YoY)
-0.66%
Earnings (YoY)
-

Profitability & Returns

ROCE
15.95%
ROE
31.22%
ROA
12.79%
Profit Margin
19.57%
Op Margin
18.58%
Gross Margin
66.08%
EPS (Latest Qtr)
$1.35
EPS (TTM)
$5.45

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$6.65B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.20%
Chg in Prom Hold
-
FII / Inst Holding
107.37%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$4.34B
EBITDA
-
Free Cash Flow
$931.00M
Operating Cash Flow
$1.08B
Shares Outstanding
-
Gross Margin
66.08%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Oct 2016Jan 2017Apr 2017Jul 2017Oct 2017Dec 2017Apr 2018Jul 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Jan 2021Apr 2021Jul 2021Oct 2021Jan 2022Apr 2022Jul 2022Oct 2022Jan 2023Apr 2023Jul 2023Oct 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue --598.00M662.00M714.00M778.00M782.00M830.00M853.00M867.00M846.00M838.00M907.00M953.00M859.00M633.00M794.00M-1.09B1.13B1.11B-1.22B1.16B1.11B-1.09B1.18B1.12B-1.08B1.11B1.08B-1.04B1.06B1.08B-1.09B1.16B
Gross Profit 426.00M419.00M368.00M434.00M482.00M542.00M538.00M575.00M597.00M590.00M584.00M573.00M648.00M662.00M619.00M428.00M526.00M-764.00M802.00M770.00M-815.00M767.00M717.00M-655.00M732.00M684.00M-667.00M721.00M745.00M-683.00M695.00M733.00M-721.00M770.00M
Operating Income 161.00M-52.00M143.00M181.00M-218.00M227.00M241.00M-204.00M205.00M308.00M-189.00M96.00M162.00M-193.00M187.00M-545.00M-184.00M-579.00M-3.66B--64.00M-88.00M-754.00M--111.00M-1.64B741.00M-164.00M214.00M227.00M-209.00M245.00M
Net Income 129.00M124.00M367.00M128.00M163.00M68.00M208.00M209.00M199.00M210.00M233.00M296.00M234.00M239.00M173.00M47.00M179.00M257.00M147.00M185.00M317.00M113.00M86.00M-535.00M-3.82B-139.00M3.00M-234.00M-754.00M-176.00M-126.00M-1.99B705.00M186.00M131.00M235.00M150.00M334.00M134.00M207.00M
Diluted EPS 0.870.842.480.871.110.461.411.411.331.411.571.991.581.611.170.321.21-1.001.262.08-0.55-3.40-24.26-0.02-1.48-4.77--0.79-12.484.42-0.821.490.98-0.871.35
R&D Expense 126.00M-145.00M130.00M134.00M-137.00M151.00M159.00M-169.00M166.00M151.00M-156.00M155.00M172.00M-197.00M202.00M436.00M-323.00M327.00M325.00M-341.00M358.00M315.00M-339.00M325.00M253.00M-252.00M247.00M229.00M-240.00M252.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Jan 2023Dec 2023Dec 2024Dec 2025
Revenue 573.23M666.32M902.74M1.06B1.15B1.42B1.86B2.22B2.40B2.75B3.33B3.54B3.24B4.53B4.58B4.50B4.37B4.34B
Gross Profit 353.09M453.88M601.54M709.10M773.53M911.89M1.30B1.55B1.67B1.83B2.30B2.47B2.20B3.15B2.97B2.74B2.86B2.87B
Operating Income 80.46M125.60M211.65M199.46M200.75M134.11M514.71M613.00M587.00M606.00M883.00M985.00M580.00M-123.00M-4.18B-1.07B-833.00M807.00M
Net Income 39.42M72.28M124.89M86.63M151.25M125.31M353.35M462.00M463.00M726.00M826.00M1.00B656.00M762.00M-4.40B-1.16B-1.22B850.00M
Diluted EPS 0.300.530.870.621.130.902.373.103.074.925.566.744.455.04-28.00-7.34-7.695.45
R&D Expense 99.96M140.62M177.95M196.91M231.03M276.74M388.06M401.00M504.00M546.00M623.00M647.00M682.00M1.19B1.32B1.35B1.17B967.00M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Jan 2023Dec 2023Dec 2024Dec 2025
Total Assets --1.43B1.84B2.20B2.57B3.02B3.34B3.69B4.28B5.26B6.96B7.32B7.58B15.22B12.25B10.11B6.30B6.64B
Total Equity 353.93M798.67M864.25M1.20B1.08B1.32B1.53B1.46B1.85B2.20B2.75B3.76B4.61B4.69B10.74B6.60B5.75B2.37B2.72B
Cash & Equivalents 174.94M327.02M144.63M248.95M302.98M433.98M711.64M636.00M769.00M735.00M1.23B1.14B-------
Long Term Debt -------986.78M1.02B1.06B1.18B890.00M1.14B673.00M-----
Current Liabilities --441.24M534.52M226.92M304.57M322.06M722.16M610.49M705.00M746.00M1.80B665.00M1.24B1.09B2.77B1.57B1.55B1.58B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Jan 2023Dec 2023Dec 2024Dec 2025
Operating Cash Flow 87.88M172.19M272.57M358.14M291.87M386.42M501.27M786.00M779.00M875.00M1.14B1.05B1.08B545.00M392.00M478.00M837.00M1.08B
Investing Cash Flow -277.25M-256.57M-285.05M-401.00M-150.01M-69.65M-406.62M-107.00M-515.00M-214.00M-1.81B745.00M-554.00M-1.07B-591.00M-231.00M-178.00M-55.00M
Financing Cash Flow 337.67M-98.86M116.47M97.02M-10.76M-38.72M-166.75M-545.00M-296.00M-176.00M594.00M-897.00M-766.00M-51.00M1.00B-1.21B-570.00M-744.00M
Capital Expenditure -59.69M-52.67M-49.82M-77.80M-68.78M-79.22M-106.00M-143.00M-260.00M-310.00M-296.00M-209.00M-189.00M-208.00M-286.00M-195.00M-128.00M-148.00M
Free Cash Flow 28.19M119.52M222.75M280.34M223.09M307.21M395.27M643.00M519.00M565.00M846.00M842.00M891.00M337.00M106.00M283.00M709.00M931.00M
Share Buybacks 70.78M175.14M44.02M570.41M82.52M50.02M237.18M274.00M249.00M251.00M201.00M324.00M736.00M000116.00M742.00M

Ratios (Annual)

Figures in %.

Metric Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Jan 2022Jan 2023Dec 2023Dec 2024Dec 2025
Gross Margin % 61.6%68.1%66.6%67.2%67.4%64.2%69.7%69.8%69.5%66.4%69.0%69.6%68.0%69.7%64.8%60.9%65.4%66.1%
Operating Margin % 14.0%18.8%23.4%18.9%17.5%9.4%27.7%27.6%24.5%22.0%26.5%27.8%17.9%-2.7%-91.2%-23.7%-19.1%18.6%
Net Margin % 6.9%10.8%13.8%8.2%13.2%8.8%19.0%20.8%19.3%26.4%24.8%28.3%20.3%16.8%-96.1%-25.8%-28.0%19.6%
ROE % 4.9%8.4%10.4%8.1%11.5%8.2%24.2%25.0%21.1%26.4%22.0%21.7%14.0%7.1%-66.7%-20.2%-51.5%31.2%
ROCE % -12.7%16.2%10.1%8.9%5.0%19.7%19.9%16.4%13.4%17.1%14.8%9.1%-0.9%-44.1%-12.5%-17.5%16.0%

Shareholding Pattern

Insiders
0.20%
Institutions
107.37%
Public Float
107.59%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ILMN

Google News Wed, 05 Aug 2026

Illumina (ILMN) Rose on Strong Clinical Momentum - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNTk1rSHBPNWl6Y1pVNTRKdkgyNUN1a29xeFA0QkNuaHdadDNmX1lhRThoUkZLSWQzVVNYVk1DOFozdTdDeGhvN2Frd1JiR3E3QVNwRmZVT01VMWxWVHRiV1M0MXNKSTBpUGZWZUVMQXFHOE9hU015dHNCbUhyMmdLalNUUDBjUHlzZGhBWE…

Google News Fri, 31 Jul 2026

Illumina (ILMN) Stock Climbs On Clinical Growth Despite Margin Pressure - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQTGEzQy1WVWFkY0tUa2VSZlFnS2Qzb1lQMW8taExucDE2aVYtenhiNXo5d0M4cUlWc0tKeWZfRE1uU093SkN6bDRwdkJFRTJrclVMTjUza1JWM3FZMlNxUnlDR2FSODY4cDlaekRlb0NjeFVmU1o4cmM2eFpFem5Fak5FQ1NwX0I1VFBvNF…

Google News ue, 04 Aug 2026

Illumina (ILMN) holder Corvex plans 840,000-share sale via Goldman Sachs - Stock Titan

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPaWVXanc2YVZtMVV4MmpGdE1KcTYyelJlamRrYVJSWVd2U0wtbmRaVkJRT3lFLW4zbDRNclpJMUw0RTJqdFg5dlFCV2dqTTRyVWxabkEwOThqbktxT1RYdkFNNkNXeVdxbG56dEd4N1JzSDZZaXJsY3lmODRNY3pzSVhBYzhvTERMci1BMW…

Google News hu, 30 Jul 2026

Illumina (ILMN) Stock Rises on Q2 2026 Earnings - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNZVpjUUI2dFBVNDRjWVBsMFhUZ0RReS1rYXphYXFMc0c0SnpCdDBpQjZiR2tzTFZVRHcxeGVKZlBEc0MyakUxZXlBN1hsQ3A4TDBBbG05MmpnZDNsU2dCMUJSdjFHbXgyYzZnUmlndXlrVzBKN1NSRk5vdDNHcWhmVUFaVTJXQkRHTExpdw…

Google News Wed, 05 Aug 2026

Illumina stock rating cut to Hold at Freedom Broker on valuation - Investing.com Canada

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQMEZvMjRCZVg5LXdRSno3UVFqczFzSDA2RHV5cm9tUElIRXlxQ3l2QkNqZkRWU1AyTDRkbGc4RjhiRjEzREs1a2M5Yi1ZdExoR2toTHdTcVpKWVBiV2p6eTR2cXZLRURmTHNfWTJuNVh5TFc3MXRENGRXQ3VyWjU4d3o3Y0tKLVFXUjBwNG…

Google News Mon, 03 Aug 2026

Illumina’s CEO Says the Clinical Growth Isn’t a Cliff. Q2 Earnings Back Him Up. - TIKR.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNdjA5R2QtM0ZqSnVWV3VFeVZmV2M2YmhSZEtQSllXVWhSY1V6MnNseWJDT294WURyLTBHMjU5dTNaejloekVFc2c2bGpvTTRpa0FhLTBOZ1Y5ZkhVZjFZaTl6N1c3a09IU3FwM1JZMlJpTjFLd2FUNXhaRTJZTDU4R0tBejlqakdpcW5PRk…

ILMN — Frequently Asked Questions

What is the current share price of ILMN?

As of 2026-08-05 17:25 PDT, ILMN trades at $199.87 on NASDAQ/NYSE. Its 52-week range is $91.00 to $205.10.

What is the P/E ratio of ILMN?

ILMN trades at a trailing price-to-earnings (P/E) ratio of 36.67.

What is the return on equity (ROE) of ILMN?

ILMN has a return on equity (ROE) of 31.22%. Its return on capital employed (ROCE) is 15.95%.

Is ILMN a good stock to buy?

This page provides a data-driven analysis of ILMN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space